Lanreotide and beyond: extending the therapeutic horizons.
Thirty years after the growth hormone inhibiting effects of somatostatin were first described, greater understanding of its activities is opening the door to potential treatments for diabetes, cancer and other disorders. Recent identification of five somatostatin receptor subtypes is allowing treatment to be carefully targeted in order to maximize efficacy, and minimize unwanted effects.
Culler
M
M
D000172:Acromegaly / Q000188:drug therapy*; D003924:Diabetes Mellitus, Type 2 / Q000188:drug therapy; D006471:Gastrointestinal Hemorrhage / Q000188:drug therapy; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy; D017481:Receptors, Somatostatin / Q000145:classification; D013004:Somatostatin / Q000819:agonists / Q000037:antagonists & inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D017481:Receptors, Somatostatin; D013004:Somatostatin